Example searches

TEVA Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Company profile

Ticker
TEVA, TEVJF
Exchange
NYSE
Website
www.teva.co.il
CEO
Kåre Schultz
Employees
Incorporated
Israel
Location
Israel
Fiscal year end
Dec 31
Sector
Health Technology > Pharmaceuticals: Generic
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Merck & Co. • Allergan • Johnson & Johnson • Abbott Laboratories • Bristol-Myers Squibb • Eli Lilly and • Warner Chilcott • AbbVie • Celgene ...
Former names
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
SEC CIK
0000818686
Corporate docs

TEVA stock data

(
)

Calendar

5 Aug 20
21 Sep 20
31 Dec 20

News

Financial summary

Financial statements Chart TEVA financial data
Quarter (USD) Jun 20 Mar 20 Sep 19 Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Recent insider trades

TEVA insider ownership history Insider history
Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
9 Sep 20 Richard Daniell Ordinary Shares Sell Dispose S Yes 8.9844 333 2.99K 10,765
9 Sep 20 Richard Daniell Ordinary Shares Option exercise Aquire M No 0 698 0 11,098
9 Sep 20 Richard Daniell Restricted Share Units Ordinary Shares Option exercise Dispose M No 0 698 0 0
2 Sep 20 Abbas Hussain Restricted Share Units Ordinary Shares Grant Aquire A No 0 13,050 0 13,050
11 Aug 20 Crane Rosemary A Ordinary Shares Sell Dispose S No 11.9013 2,860 34.04K 33,509
11 Aug 20 Crane Rosemary A Ordinary Shares Option exercise Aquire M No 0 7,956 0 36,369
11 Aug 20 Crane Rosemary A Restricted Share Units Ordinary Shares Option exercise Dispose M No 0 7,956 0 0
11 Aug 20 Elstein Amir Ordinary Shares Option exercise Aquire M No 0 7,956 0 2,024,225
11 Aug 20 Elstein Amir Restricted Share Units Ordinary Shares Option exercise Dispose M No 0 7,956 0 0
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q2 2020

TEVA institutional ownership history Ownership history
52.7% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 448 454 -1.3%
Opened positions 58 88 -34.1%
Closed positions 64 76 -15.8%
Increased positions 127 149 -14.8%
Reduced positions 143 113 +26.5%
13F shares
 Current Prev Q Change
Total value 48.99B 35.27B +38.9%
Total shares 577.38M 545.5M +5.8%
Total puts 21.53M 43.52M -50.5%
Total calls 21.7M 25.84M -16.0%
Total put/call ratio 1.0 1.7 -41.1%
Largest owners
 Shares Value Change
Capital Research Global Investors 130.13M $1.6B +0.0%
Capital World Investors 43.43M $535.5M +31.3%
BRK.A Berkshire Hathaway 42.79M $527.59M 0.0%
BLK BlackRock 37.62M $463.84M -0.3%
Abrams Capital Management 24.05M $296.49M 0.0%
Migdal Insurance & Financial 21.87M $269.69M -0.4%
Capital International Investors 20.51M $252.88M +47.7%
Menora Mivtachim 17.93M $221.02M +8.3%
Clal Insurance Enterprises 16.42M $202.44M +23.3%
STT State Street 15.66M $193.15M +1.7%
Largest transactions
 Shares Bought/sold Change
Capital World Investors 43.43M +10.34M +31.3%
FMR 8.17M +7.02M +608.9%
Capital International Investors 20.51M +6.63M +47.7%
Jane Street 579.09K -5.46M -90.4%
Ion Asset Management 5.18M +5.18M NEW
Clal Insurance Enterprises 16.42M +3.11M +23.3%
Arrowstreet Capital, Limited Partnership 4.88M +2.22M +83.4%
Partner Fund Management 2.03M +2.03M NEW
Camber Capital Management 2M +2M NEW
Orbimed Advisors 1.94M +1.94M NEW
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Akorn • Teligent • Spectrum Pharmaceuticals • Actavis • ARIAD Pharmaceuticals • Nektar Therapeutics • Neurocrine Biosciences • Acorda Therapeutics • Innoviva • NeuBase Therapeutics
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: acquisitionof, additi, Afinitor, airway, Alvotech, amplify, analyst, arm, asa, asan, avoid, banc, bellwether, BrandName, budesonide, cal, cerebral, Chicago, chose, closure, companion, constitute, correlating, couldhave, criminal, ctive, dermatological, detriment, digital, discovered, Distric, doctor, dominant, ed, EIB, endedJune, ernment, EU, expert, FACT, fewer, field, fil, formal, Francisco, Genericsresulting, Genericsthat, Goa, gov, hs, Ill, impairm, includematerial, ingredient, inhibiting, introduction, irbesartan, itwith, LaunchDate, losartan, maximum, mcg, milliongain, millionin, mobile, mont, monthly, nineteen, nominally, numerical, obstructive, ofcertain, ofcontract, ofthe, overseeing, palsy, physical, placebo, powder, precipitate, prescription, pro, protectionist, protest, Protracted, Pulmicort, ranitidine, rehearingen, rescue, respectiv, Rituxan, Romidepsin, San, Seco, sha, shift, showed, stake, stand, statistical, stemming, thea, theperiod, threeand, Timeof, ts, upper, vincial, Virgin, water, week, yearperiod
Removed: assumed, capped, cease, Chapter, comparative, dissolution, Gamble, gap, half, located, low, matured, model, nonrecurring, ordered, overturned, ownership, PGT, Procter, provincial, reclassified, repayment, responding, separation, transition
From filing 10-Q 2020 Q2

Financial reports

View all
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
21 Feb 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
2 May 19
10-K
2018 FY
Annual report
19 Feb 19
10-Q
2018 Q3
Quarterly report
1 Nov 18
10-Q
2018 Q2
Quarterly report
2 Aug 18
10-Q
2018 Q1
Quarterly report
3 May 18

Current reports

View all
8-K
Departure of Directors or Certain Officers
6 Aug 20
8-K
Results of Operations and Financial Condition
5 Aug 20
8-K
Departure of Directors or Certain Officers
9 Jun 20
8-K
Results of Operations and Financial Condition
7 May 20
8-K
Results of Operations and Financial Condition
12 Feb 20
8-K
Entry into a Material Definitive Agreement
25 Nov 19
8-K
Departure of Directors or Certain Officers
7 Nov 19
8-K
Results of Operations and Financial Condition
7 Nov 19
8-K
Regulation FD Disclosure
23 Oct 19
8-K
Departure of Directors or Certain Officers
2 Oct 19

Registration and prospectus

View all
424B3
Prospectus supplement
17 Aug 20
S-4
Registration of securities issued in business combination transactions
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8
Registration of securities for employees
5 Aug 20
F-6
Registration for ADRs (foreign)
13 Nov 18
424B3
Prospectus supplement
19 Apr 18

Proxies

DEFA14A
Additional proxy soliciting materials
26 May 20
DEFA14A
Additional proxy soliciting materials
22 Apr 20
DEF 14A
Definitive proxy
22 Apr 20
PRE 14A
Preliminary proxy
19 Mar 20
DEFA14A
Additional proxy soliciting materials
16 Apr 19
DEF 14A
Definitive proxy
16 Apr 19
DEF 14A
Definitive proxy
25 Apr 18
DEFA14A
Additional proxy soliciting materials
25 Apr 18

Other

View all
EFFECT
Notice of effectiveness
18 Aug 20
SD
Conflict minerals disclosure
14 Aug 20
CORRESP
Correspondence with SEC
13 Aug 20
CORRESP
Correspondence with SEC
13 Aug 20
UPLOAD
Letter from SEC
11 Aug 20
UPLOAD
Letter from SEC
15 Jul 20
CORRESP
Correspondence with SEC
19 Jun 20
CORRESP
Correspondence with SEC
17 Apr 20
SD
Conflict minerals disclosure
31 May 19
EFFECT
Notice of effectiveness
4 Dec 18

Ownership

View all
4
TEVA PHARMACEUTICAL INDUSTRIES / Richard Daniell ownership change
10 Sep 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Abbas Hussain ownership change
3 Sep 20
3
TEVA PHARMACEUTICAL INDUSTRIES / Abbas Hussain ownership change
3 Sep 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Nechemia Jacob Peres ownership change
13 Aug 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Perry Nisen ownership change
13 Aug 20
4
TEVA PHARMACEUTICAL INDUSTRIES / ROBERTO MIGNONE ownership change
13 Aug 20
4
TEVA PHARMACEUTICAL INDUSTRIES / GERALD M LIEBERMAN ownership change
13 Aug 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Jean Michel Halfon ownership change
13 Aug 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Amir Elstein ownership change
13 Aug 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Rosemary A Crane ownership change
13 Aug 20

Patents

View all
APP
Utility
Medroxyprogesterone Acetate Injectable Compositions and Methods of Use
10 Sep 20
The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml or about 160 mg/ml to 240 mg/ml medroxyprogesterone acetate, 1.2 mg/ml to 3.0 mg/ml docusate sodium, polyethylene glycol, and water.
APP
Utility
Solid State Forms of Elafibranor
10 Sep 20
Disclosed are solid state forms of Elafibranor and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
APP
Utility
Solid State Forms of Trisodium Valsartan: Sacubitril
3 Sep 20
Solid state forms of trisodium valsartan:sacubitril, processes for their preparation, pharmaceutical compositions containing such solid state forms and treatment methods using the pharmaceutical compositions are described.
GRANT
Utility
Process for preparing quinolin-2-yl-phenylamine derivatives and their salts
18 Aug 20
Inventors: Sebastian Rabe, Wolfgang Albrecht
APP
Utility
Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
6 Aug 20
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody.